USX:BIOC - Biocept Inc (USD 0.282) Biocept Inc
Sector: Health Technology, Industry: Medical Specialties
Add to Watchlist
   


Yahoo Finance

USD 0.282    +0.015 (+5.62%)
Show Basic Chart | 3M    6M    1Y    3Y    5Y          

3 Apr 2020


Overview

3 Apr 2020

Day Change: 0.015 (5.62%)

52 Wk Range: 0.2112 - 2.11

Day's Range: 0.2541 - 0.2838

Last Volume: 5,881,807

Current Yield: 0%

Projected Yield: 0%

Open: USD 0.2699

3 Apr 2020

Metric BIOC S.Median
Beta 0.78 0.77
VaR 883.76 46.1
E.Shortfall 883.76 76.92
Liquidity 6.65M 22.95K

Fundamental

3 Apr 2020

PE: -0.255

Market Cap: 6.5M

Price Over Book: 0.842

Price Over Sales: 1.41

Return On Assets: -175.2%

Return On Equity: -330.1%

NAV Over Price: [Friends Only]

General

CEO: Michael W. Nall

Headquarters: SAN DIEGO

Employees: 42

Sector: Health Technology

Industry: Medical Specialties

Useful Links
Homepage

Description

Biocept, Inc., an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample. The company's cancer assays provide information to oncologists and other physicians that enable them to select personalized treatment for their patients who have been diagnosed with cancer based on molecular drivers. It offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer, small cell lung cancer, gastric cancer, colorectal cancer, prostate cancer, and melanoma. The company sells its cancer diagnostic assays directly to oncologists and other physicians at private and group practices, hospitals, and cancer centers in the United States, as well as markets its clinical trial and research services to pharmaceutical and biopharmaceutical companies, and clinical research organizations. Biocept, Inc. was founded in 1997 and is headquartered in San Diego, California.